Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Other Non Operating Income: 2016-2025

Historic Other Non Operating Income for Zevra Therapeutics (ZVRA) over the last 2 years, with Sep 2025 value amounting to -$6.6 million.

  • Zevra Therapeutics' Other Non Operating Income rose 2.58% to -$6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.9 million, marking a year-over-year increase of 1807.37%. This contributed to the annual value of $6.2 million for FY2024, which is 340.28% up from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Other Non Operating Income is -$6.6 million, which was down 104.85% from $135.4 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Other Non Operating Income ranged from a high of $135.4 million in Q2 2025 and a low of -$16.9 million during Q1 2021.
  • Its 2-year average for Other Non Operating Income is $17.8 million, with a median of -$3.4 million in 2025.
  • Data for Zevra Therapeutics' Other Non Operating Income shows a peak YoY skyrocketed of 7,470.08% (in 2025) over the last 5 years.
  • Over the past 3 years, Zevra Therapeutics' Other Non Operating Income (Quarterly) stood at $789,000 in 2021, then reached $7.5 million in 2024, then climbed by 2.58% to -$6.6 million in 2025.
  • Its last three reported values are -$6.6 million in Q3 2025, $135.4 million for Q2 2025, and -$3.4 million during Q1 2025.